Skip to main content
Fig. 4 | Respiratory Research

Fig. 4

From: Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial

Fig. 4

Identification and nasal symptom scores of improved and non-improved patients. a Identification of patients reporting change in allergic symptoms 30 min after nasal allergen provocation (NPT), as well as change of seasonal allergic symptoms (VAS-score 0 = no improvement; VAS-score: 10 = complete recovery) after treatment. “Improved” patients are depicted with a black box. Non-improved patients are depicted with a grey box. b Self-reported allergic symptoms 30 min after nasal allergen provocation before treatment, four weeks after treatment and following the consecutive pollen season in improved, non-improved and placebo patients *p < 0.05 using a repeated measures ANOVA followed by a Dunnet’s multiple comparison post-test. ILIT: Intralymphatic immunotherapy

Back to article page